These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23553358)

  • 1. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
    Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
    Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
    BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
    Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
    Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
    Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
    Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics.
    Reitan JF; van Breda A; Shreay S; Corey-Lisle PK; Cong Z
    Hosp Pharm; 2013 Feb; 48(2):120-6. PubMed ID: 24421449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
    Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
    J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
    Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
    Borget I; Chouaid C; Demarteau N; Annemans L; Pujol JL
    Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
    Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
    Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy.
    McGarvey N; Xu H
    J Health Econ Outcomes Res; 2016; 3(2):214-223. PubMed ID: 37663317
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.
    Crémieux PY; Fastenau JM; Kosicki G; Piech CT; Fendrick AM
    J Manag Care Pharm; 2004; 10(6):531-7. PubMed ID: 15548125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
    Muller RJ; Baribeault D
    Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of long-acting growth factors on practice dynamics and patient satisfaction.
    Beveridge RA; Rifkin RM; Moleski RJ; Milkovich G; Reitan JF; Paivanas TA; Jacobs RJ
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):101S-109S. PubMed ID: 14694999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.